Literature DB >> 33532781

Sequence signatures of two IGHV3-53/3-66 public clonotypes to SARS-CoV-2 receptor binding domain.

Timothy J C Tan1, Meng Yuan2, Kaylee Kuzelka3, Gilberto C Padron3, Jacob R Beal3, Xin Chen1, Yiquan Wang3, Joel Rivera-Cardona4, Xueyong Zhu2, Beth M Stadtmueller3, Christopher B Brooke4,5, Ian A Wilson2,6,7,8, Nicholas C Wu1,3,5.   

Abstract

Since the COVID-19 pandemic onset, the antibody response to SARS-CoV-2 has been extensively characterized. Antibodies to the receptor binding domain (RBD) on the spike protein are frequently encoded by IGHV3-53/3-66 with a short CDR H3. Germline-encoded sequence motifs in CDRs H1 and H2 play a major role, but whether any common motifs are present in CDR H3, which is often critical for binding specificity, have not been elucidated. Here, we identify two public clonotypes of IGHV3-53/3-66 RBD antibodies with a 9-residue CDR H3 that pair with different light chains. Distinct sequence motifs on CDR H3 are present in the two public clonotypes that appear to be related to differential light chain pairing. Additionally, we show that Y58F is a common somatic hypermutation that results in increased binding affinity of IGHV3-53/3-66 RBD antibodies with a short CDR H3. Overall, our results advance fundamental understanding of the antibody response to SARS-CoV-2.

Entities:  

Year:  2021        PMID: 33532781      PMCID: PMC7852275          DOI: 10.1101/2021.01.26.428356

Source DB:  PubMed          Journal:  bioRxiv


  69 in total

1.  Sequences of mouse immunoglobulin light chain genes before and after somatic changes.

Authors:  O Bernard; N Hozumi; S Tonegawa
Journal:  Cell       Date:  1978-12       Impact factor: 41.582

2.  Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2020-12-02

3.  Human neutralizing antibodies elicited by SARS-CoV-2 infection.

Authors:  Bin Ju; Qi Zhang; Jiwan Ge; Ruoke Wang; Jing Sun; Xiangyang Ge; Jiazhen Yu; Sisi Shan; Bing Zhou; Shuo Song; Xian Tang; Jinfang Yu; Jun Lan; Jing Yuan; Haiyan Wang; Juanjuan Zhao; Shuye Zhang; Youchun Wang; Xuanling Shi; Lei Liu; Jincun Zhao; Xinquan Wang; Zheng Zhang; Linqi Zhang
Journal:  Nature       Date:  2020-05-26       Impact factor: 49.962

4.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.

Authors:  Rui Shi; Chao Shan; Xiaomin Duan; Zhihai Chen; Peipei Liu; Jinwen Song; Tao Song; Xiaoshan Bi; Chao Han; Lianao Wu; Ge Gao; Xue Hu; Yanan Zhang; Zhou Tong; Weijin Huang; William Jun Liu; Guizhen Wu; Bo Zhang; Lan Wang; Jianxun Qi; Hui Feng; Fu-Sheng Wang; Qihui Wang; George Fu Gao; Zhiming Yuan; Jinghua Yan
Journal:  Nature       Date:  2020-05-26       Impact factor: 49.962

5.  Convergent antibody signatures in human dengue.

Authors:  Poornima Parameswaran; Yi Liu; Krishna M Roskin; Katherine K L Jackson; Vaishali P Dixit; Ji-Yeun Lee; Karen L Artiles; Simona Zompi; Maria José Vargas; Birgitte B Simen; Bozena Hanczaruk; Kim R McGowan; Muhammad A Tariq; Nader Pourmand; Daphne Koller; Angel Balmaseda; Scott D Boyd; Eva Harris; Andrew Z Fire
Journal:  Cell Host Microbe       Date:  2013-06-12       Impact factor: 21.023

6.  In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity.

Authors:  Nicholas C Wu; Geramie Grande; Hannah L Turner; Andrew B Ward; Jia Xie; Richard A Lerner; Ian A Wilson
Journal:  Nat Commun       Date:  2017-05-15       Impact factor: 14.919

Review 7.  SARS-CoV-2 Vaccines: Status Report.

Authors:  Fatima Amanat; Florian Krammer
Journal:  Immunity       Date:  2020-04-06       Impact factor: 31.745

8.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.

Authors:  Yushun Wan; Jian Shang; Rachel Graham; Ralph S Baric; Fang Li
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

9.  Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.

Authors:  Yiska Weisblum; Fabian Schmidt; Fengwen Zhang; Justin DaSilva; Daniel Poston; Julio Cc Lorenzi; Frauke Muecksch; Magdalena Rutkowska; Hans-Heinrich Hoffmann; Eleftherios Michailidis; Christian Gaebler; Marianna Agudelo; Alice Cho; Zijun Wang; Anna Gazumyan; Melissa Cipolla; Larry Luchsinger; Christopher D Hillyer; Marina Caskey; Davide F Robbiani; Charles M Rice; Michel C Nussenzweig; Theodora Hatziioannou; Paul D Bieniasz
Journal:  Elife       Date:  2020-10-28       Impact factor: 8.140

10.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.